FOR IMMEDIATE RELEASE
CONTACT: Daina Basile
Kovak-Likly Communications
203-762-8833, dbasile@klcpr.com
YARAL PHARMA LAUNCHES LIDOCAINE PATCH 5%
Expands its Line of Non-Opioid Prescription Medications
PARSIPPANY, NJ – September 1, 2023 – Yaral Pharma Inc., (Yaral Pharma), the United States generics subsidiary of IBSA (Institut Biochimique SA), one of the world’s leaders in transdermal and topical patch technology, today announced the launch of Lidocaine Patch 5%, an AB-rated equivalent to Lidoderm® (lidocaine topical patch 5%). Yaral Pharma’s prescription-strength lidocaine is the latest addition to its pain and inflammation portfolio which includes medications that help meet the growing demand for non-opioid prescription products.
“Yaral Pharma is committed to meeting customer needs with high-quality products supported by exceptional customer service,” said Stephen Beckman, CEO, Yaral Pharma. “At a time when customers may be experiencing challenges sourcing lidocaine, we are pleased to be able to harness our company’s drug delivery technology expertise to bring patients an accessible and affordable non-opioid prescription medication for local pain management.”
Customers can order Yaral Pharma’s, prescription-strength Lidocaine Patch 5% by calling
| 866-218-9009. Product | Strength | NDC # | Package Size |
| Lidocaine Patch | 5% | 82347-0505-5 | 30-patch carton |
Altergon Italia, a longstanding strategic partner of IBSA that specializes in the production of drug delivery systems, including transdermal patches, will manufacture the product for Yaral Pharma. The Company will be launching in the third quarter of 2023 and progressively working towards meeting market demand.
Earlier this year, Yaral Pharma launched its first authorized generic (AG), Diclofenac Epolamine Topical System, 1.3% – a prescription only, nonsteroidal anti-inflammatory (NSAID) medicated patch used to treat acute pain due to minor strains, sprains, and contusions. As a company dedicated to ensuring access to affordable AGs and complex generic medicines, Yaral Pharma has made great strides in driving access to its lead AG across the US and its territories.
Yaral Pharma is poised to continue expanding its product line with additional commercial launches driven organically and through outside opportunities and external partnerships with a focus on oral solid dosage (OSD), complex generic medicines and 505(b)2 products. The Company’s current portfolio includes products in the therapeutic areas of pain and endocrinology with future expansion planned in the areas of rheumatology, human reproduction, and dermo-aesthetics. For the latest updates on Yaral Pharma, visit www.yaralpharmainc.com or connect with us on LinkedIn.
About IBSA’s Patch Technology
IBSA specializes in developing and producing patent-protected medicated patches that release medication through the skin into the bloodstream. These patches are made using hydrogel and drug-in-adhesive technologies and can act locally or systemically.
Transdermal patches provide controlled release of medication, maintaining optimal concentration and reducing the need for frequent administration. They also enhance bioavailability and minimize side effects. IBSA’s expertise and production capacity make the Company a leading manufacturer of topical patches.
About Yaral Pharma
Yaral Pharma Inc. (Parsippany, NJ) is the US generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they’re cared for, Yaral Pharma is proud to offer the same values and expertise of its parent company to the US market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, Yaral Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service. For more information, visit www.yaralpharmainc.com or contact info@yaral-pharma.com or 866-218-9009.
About Altergon Italia
Altergon Italia is an innovative and technological CDMO specializing in the development of new Drug Delivery Systems. Located in Italy for 20 years, Altergon has the know-how and state-of-the-art facilities to lead the worldwide market with regard to the production of medicated patches (Hydrogel and Drug-in-adhesive), Orodispersible Films, Hyaluronic Acid cross-linked pre-filled syringes and sterile Hyaluronic Acid impregnated gauzes.
The Company is a world leading Centre of Excellence & Innovation for the patented biotech production of injectable Sodium Hyaluronate bulk for pharmaceutical purpose. Altergon continuously invests in Research and Development activities in order to innovate and increase its gamma of products in the biotech, pharmaceutical, dermocosmetic and diagnostics fields in collaboration with Universities and Research Institutes.
Important Safety Information for Lidocaine Patch 5%
Please refer to the full Prescribing Information for Lidocaine Patch 5% here. You are encouraged to report suspected adverse reactions to Yaral Pharma by emailing MI@yaral-pharma.com or calling 866-218-9009, or to the FDA by visiting http://www.fda.gov/medwatch.
Important Safety Information for Diclofenac Epolamine Topical System, 1.3%
WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS
Cardiovascular Thrombotic Events
• Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious
cardiovascular thrombotic events, including myocardial infarction and stroke, which can
be fatal. This risk may occur early in the treatment and may increase with duration of
use.
• Diclofenac epolamine topical system 1.3% is contraindicated in the setting of coronary
artery bypass graft (CABG) surgery.
Gastrointestinal Bleeding, Ulceration, and Perforation
• NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including
bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
These events can occur at any time during use and without warning symptoms. Elderly
patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at
greater risk for serious GI events.
Please refer to the full Prescribing Information, including Boxed Warning for diclofenac epolamine topical system, 1.3% here.
You are encouraged to report suspected adverse reactions to Yaral Pharma by emailing MI@yaral-pharma.com or calling 866-218-9009 or to the FDA by visiting http://www.fda.gov/medwatch.
Lidoderm® is a registered trademark of Hind Health Care, Inc.